A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 07 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 20 Feb 2015 New source identified and integrated (M.D. Anderson Cancer Center record:2014-0081) record.
- 20 Feb 2015 According to the M.D. Anderson Cancer Center record, status changed from not yet recruiting to recruiting.